Updated COVID-19 vaccines matched to the XFG variant were approved on August 27 and began shipping the same day, putting new doses in pharmacies, hospitals, and clinics across the country within days. Pfizer and BioNTech confirmed approval of their 2026-2027 formula, and Moderna and the Novavax-Sanofi partnership announced approvals of their own updated shots.
What did not arrive alongside the vaccines is a federal statement on who should get one. The Advisory Committee on Immunization Practices, the panel that normally converts an FDA approval into a public recommendation and a coverage guarantee, has been without a functioning quorum since a court ruling in March. That leaves the practical decision to patients, their clinicians, and their pharmacists.
For most households, the immediate consequence is narrower than it sounds, but it is not invisible. Whether a healthy 40-year-old can walk into a chain pharmacy and get a shot without a prescription now depends less on federal guidance than on state pharmacy rules and individual store policy. Families planning around a grandparent's care, a chronic condition, or holiday travel should expect to make a phone call before they make an appointment.
Shots Are Shipping Before the Guidance Catches Up
Pfizer and BioNTech's Comirnaty XFG is approved for adults 65 and older and for people ages 5 through 64 who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, according to the companies' approval announcement. The FDA based its decision on the accumulated clinical, non-clinical, and real-world evidence from earlier Comirnaty formulations, combined with manufacturing and non-clinical data specific to the strain change.
Eligibility differs slightly across the other approved vaccines. Moderna received approval for two mRNA vaccines targeting XFG: Spikevax for people 6 months through 64 with an underlying condition and anyone 65 or older, and mNexspike for people 12 through 64 with an underlying condition and anyone 65 or older. Nuvaxovid, the protein-based option from Novavax and Sanofi, was cleared for everyone 65 and older and for people 12 through 64 with underlying conditions.
That sequence is normal. The strain decision was settled in late May, when the FDA's vaccine advisory committee voted to target XFG and the agency adopted the recommendation the next day. MedicalDaily reported at the time on the missing second step, noting that the FDA sets the formula while the advisory committee decides who should receive it and how it is paid for.
Three months later, that second step still has not happened. Tracking published by CIDRAP at the University of Minnesota in July confirmed the committee remained without a quorum, with the underlying litigation moving on an expedited appeal schedule. Readers should treat that as the most recent verified status rather than a permanent condition.
Insurance Coverage Holds, but Access Varies by Counter
The coverage picture is more settled than the guidance picture, though not entirely settled. AHIP, the national trade association for health insurance providers, has committed to covering all immunizations recommended by the advisory committee with no cost sharing through the end of 2027.
There is a gap worth understanding within that commitment. For private plans, Medicare Part D, and Medicaid expansion, the no-cost coverage requirement is tied to a recommendation adopted by the CDC director. Because each season's updated COVID formula is treated as new, and because no current-season recommendation exists, coverage for this particular shot rests on plan-level decisions and prior-year recommendations rather than on a fresh federal trigger. Checking with the plan before the visit is the only reliable way to know.
Access is the softer point. Standing CDC guidance frames COVID vaccination for people 6 months and older around individual decision-making with a clinician, though that page still describes the 2025-2026 formula and has not been updated for the new season. In practice, some states allow pharmacists to vaccinate adults directly, some require a prescription for people outside the approved age and risk groups, and chain policies vary. Calling ahead is the single most useful step a household can take this week.
Older Adults and Higher Risk Households Carry the Clearest Benefit
The people with the strongest case for an updated dose are the same ones who have carried the most severe outcomes throughout the pandemic: adults 65 and older, people who are moderately or severely immunocompromised, and adults and children with conditions such as diabetes, chronic lung disease, heart disease, obesity, or pregnancy.
Risk is not evenly distributed. A healthy 28-year-old with no risk conditions faces a materially different calculation than a 78-year-old on immunosuppressive therapy. Both may reasonably choose vaccination, but only one has an approval clearly written for them.
Parents of school-age children face the most ambiguity. Pfizer's approval covers children 5 and older only when a qualifying risk condition is present, while Moderna's Spikevax reaches down to 6 months on the same risk basis. Families with younger children or children who do not have a qualifying condition should raise the question with a pediatrician rather than assuming a pharmacy can resolve it.
Caregivers managing an older relative have the most concrete task. Confirming a nursing facility's vaccination schedule, checking whether a home health provider carries doses, and asking whether a coexisting condition changes the timing are all worth doing before respiratory season builds.
Open Questions Heading Into Fall
Several things remain genuinely unknown. There is no confirmed date for an advisory committee meeting that could produce a 2026-2027 recommendation. It is not established how many pharmacies will vaccinate people who fall outside the approved age and risk criteria. Real-world effectiveness data for the XFG formula does not yet exist, because the vaccines were approved on immunogenicity, manufacturing, and prior clinical evidence rather than a new efficacy trial.
What is confirmed is narrow and useful. The formula matches lineages that circulated this summer. Doses are shipping. Insurer coverage commitments extend through 2027. Anyone who wants a shot should verify eligibility with their pharmacy or clinician first, ask whether a prescription is needed in their state, and confirm coverage with their plan before the visit. Nobody should stop or change a prescribed medication because of a vaccination decision, and anyone with a history of a severe reaction to a COVID vaccine should raise it with a clinician rather than a pharmacy counter.
MedicalDaily will report any advisory committee meeting notice, CDC guidance update or coverage change as it is published.
Key Questions Answered
What exactly did the FDA approve? Updated 2026-2027 COVID-19 vaccine formulas from Pfizer-BioNTech, Moderna, and the Novavax-Sanofi partnership. The Pfizer and Moderna formulas target the XFG variant. The approvals were announced on August 27, 2026.
Who is eligible for the Pfizer-BioNTech shot? Adults 65 and older, and people ages 5 through 64 who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
Will insurance cover it? AHIP member plans have committed to covering immunizations recommended by the federal advisory committee with no cost sharing through the end of 2027. Because no current-season recommendation exists, coverage details vary by plan, and self-insured employer plans may differ.
Why has no federal recommendation been issued? The CDC advisory committee that issues those recommendations has lacked a functioning quorum since a federal court ruling in March 2026. The FDA sets the vaccine formula; the committee normally sets who is eligible and the coverage terms.
Can a pharmacist vaccinate someone outside the approved groups? It depends on the state and the pharmacy. Some states permit pharmacists to vaccinate adults directly, while others require a prescription. Call before booking.
When should someone talk to a doctor instead? Anyone who is pregnant, immunocompromised, has had a severe reaction to a previous COVID vaccine, or is deciding for a very young child should raise the question with a clinician rather than resolving it at a pharmacy counter.
What happens next? No advisory committee meeting date has been confirmed. Any updated recommendation, CDC guidance change, or insurer policy shift would be published directly by those bodies.
